紧急要求扩大普雷托曼尼德的标签,以符合世卫组织的指导方针,并提高治疗的可访问性和有效性
L Kuksa1, C Andrejak2, B Haecker3
1Riga East University Hospital, Tuberculosis and Lung Disease center, Riga, Latvia.
IJTLD open
|March 17, 2025
概括
普雷托曼尼德是治疗结核病 (TB) 的重要药物. 专家们主张将其批准的用途扩展到目前针对耐药结核病的严格BPaL疗法之外,与全球治疗指南保持一致.
科学领域:
- 药理学 药理学是指药理学的学科.
- 传染性疾病 传染性疾病
- 公共卫生 公共卫生
背景情况:
- 普雷托曼尼德是世界卫生组织列出的关键抗结核病 (TB) 药物之一.
- 目前欧洲药物管理局 (EMA) 的批准将普雷托曼尼德限制在BPaL疗法 (贝达基林,普雷托曼尼德,线索利德) 中.
- 这种限制性使用仅限于广泛耐药结核病 (XDR-TB) 或多药耐药结核病 (MDR-TB) 病例,这些病例对其他治疗不反应或不耐受.
研究的目的:
- 倡导扩大普雷托曼尼德的EMA批准的标签.
- 为了使该药物的批准指示与当前国际治疗耐药结核病治疗指南保持一致.
- 促进更广泛地获得有效的结核病治疗方案.
主要方法:
- 专家的共识和呼吸组织和协会的立场声明.
- 审查目前EMA批准的前提曼尼德的标签.
- 与耐药结核病全球治疗指南的比较.
主要成果:
- 目前EMA批准的普雷托曼尼德的标签过于严格.
- 这种限制迫使许多患者继续使用较旧,效果较差,耐受性较差的结核病治疗方案.
- 更广泛地使用普雷托曼尼德可以改善耐药结核病的治疗结果.
结论:
- 普雷托曼尼德的标签应该扩大,以促进更广泛的临床应用.
- 扩大普雷托曼尼德的使用将与全球建议保持一致,并改善耐药结核病患者的护理.
- 这一变化对于克服当前治疗标准的局限性至关重要.
相关概念视频
Drug Therapy
32
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
32
Antidepressant Drugs: MAOIs and Other Agents
174
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
174
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
141
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
141
Drug Nomenclature
1.6K
During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that...
1.6K
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
201
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
201
Drugs for Treatment of Diarrhea-Predominant IBS
133
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
133


